The estimated Net Worth of Scott Moomaw is at least $1.71 Milion dollars as of 30 August 2024. Mr Moomaw owns over 1,875 units of Liquidia Corp stock worth over $1,571,941 and over the last 4 years he sold LQDA stock worth over $138,884.
Mr has made over 12 trades of the Liquidia Corp stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 1,875 units of LQDA stock worth $19,031 on 30 August 2024.
The largest trade he's ever made was exercising 7,650 units of Liquidia Corp stock on 10 November 2021 worth over $77,648. On average, Mr trades about 1,988 units every 54 days since 2020. As of 30 August 2024 he still owns at least 154,871 units of Liquidia Corp stock.
You can see the complete history of Mr Moomaw stock trades at the bottom of the page.
Scott Moomaw is the Sr. VP of Commercial at Liquidia Corp.
Mr Moomaw is 50, he's been the Sr. VP of Commercial of Liquidia Corp since . There are 14 older and 6 younger executives at Liquidia Corp. The oldest executive at Liquidia Corp is Ralph Snyderman, 80, who is the Independent Director.
Scott's mailing address filed with the SEC is 419 DAVIS DRIVE, SUITE 100, , MORRISVILLE, NC, 27560.
Over the last 6 years, insiders at Liquidia Corp have traded over $16,750,945 worth of Liquidia Corp stock and bought 12,456,625 units worth $100,694,400 . The most active insiders traders include Forest Baskett, Scott D Sandell a Peter J Barris. On average, Liquidia Corp executives and independent directors trade stock every 18 days with the average trade being worth of $1,467,274. The most recent stock trade was executed by Russell Schundler on 30 August 2024, trading 2,344 units of LQDA stock currently worth $23,792.
liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.
Liquidia Corp executives and other stock owners filed with the SEC include: